Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) has announced its upcoming third quarter 2024 financial results conference call, scheduled for Thursday, November 7, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website at https://investor.pacificbiosciences.com/.
For those preferring a dial-in option, the following numbers are provided:
- Toll-free: 1-888-349-0136
- International: 1-412-317-0459
Participants using the dial-in option are advised to join the call ten minutes before the start time and ask to join the 'PacBio Q3 Earnings Call'. A replay of the webcast will be available on the company's investor relations website after the call.
PacBio, A*STAR, and Macrogen have opened a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (GIS) in Singapore. This facility will provide local researchers access to cutting-edge long-read sequencing technology, marking a significant milestone for HiFi long-read sequencing applications in precision medicine, population genomics, and health and disease biology in Southeast Asia.
The lab will house two PacBio Revio systems, known for their scalability, high throughput, and ease of use. These systems feature PacBio's proprietary HiFi sequencing technology, offering highly accurate long reads ideal for complex genomic studies and real-time methylation detection. Macrogen will provide streamlined sequencing service support, positioning the lab as a hub for genomics innovation in Singapore.
This collaboration aims to strengthen Singapore's position as a global leader in genomics research, supporting the National Precision Medicine (NPM) long-read sequencing needs and serving as a vital resource for researchers in fields such as population genetics, cancer research, and rare disease studies.
The HiFi Solves Sub-fertility Consortium, led by KK Women's and Children's Hospital in Singapore, is leveraging PacBio HiFi long-read sequencing to improve diagnosis and treatment of subfertility and recurrent pregnancy loss (RPL). This collaboration involves five leading centers across the Asia-Pacific region and utilizes DNAstack's federated data platform for secure, efficient global collaboration.
The consortium aims to revolutionize fertility research by offering a more comprehensive and high-resolution approach to identifying complex chromosomal rearrangements and sub-microscopic abnormalities. This initiative is expected to reduce the 'diagnostic odyssey' for patients and enhance the success of assisted reproductive technologies. The project, spanning through 2025, includes patient recruitment, advanced sequencing, and bioinformatics analysis, with the goal of influencing clinical practices globally.
PacBio (NASDAQ: PACB) has announced a collaboration with the University Hospital of Münster to advance male infertility and rare disease research using long-read whole genome sequencing. The university will deploy PacBio's Revio HiFi sequencing system to obtain highly accurate genomic data, particularly for studying the Y chromosome's role in male infertility. This initiative is part of Germany's GenomeDE Modellvorhaben project and will contribute to the International Male Infertility Genomics Consortium.
The University of Münster aims to sequence 500 patients with male infertility over the next year and conduct trio sequencing of rare disease families. The research will support Germany's efforts to integrate genomic medicine into standard patient care and advance understanding of rare diseases, developmental delay, and cancer.
PacBio (NASDAQ: PACB), a top developer of high-quality sequencing solutions, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 5, at 1:05 p.m. Eastern Time.
The event will be live-streamed on PacBio's investors page at investor.pacificbiosciences.com. For those unable to attend live, a replay will be available for at least 30 days following the event. This presentation offers investors and interested parties an opportunity to gain insights into PacBio's latest developments and future prospects in the sequencing technology sector.
PacBio (NASDAQ: PACB) reported Q2 2024 financial results with revenue of $36.0 million, down from $47.6 million in Q2 2023. The company faced headwinds in the capital equipment market, particularly in Europe and Asia. Key highlights include:
- Instrument revenue: $14.7 million (24 Revio™ systems sold)
- Consumables revenue: $17.0 million
- Service and other revenue: $4.3 million
- Net loss: $173.3 million ($0.64 per share)
- Non-GAAP net loss: $55.2 million ($0.20 per share)
Despite challenges, PacBio sees positive developments in population genomics programs and increasing adoption of Revio in clinical research. The company remains on track to reduce annual run rate expenses by over $75 million while maintaining key product development programs.
PacBio (NASDAQ: PACB) has partnered with Singapore's National Precision Medicine (NPM) programme to advance HiFi Sequencing in Southeast Asia. Precision Health Research, Singapore (PRECISE) has selected PacBio's Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project, aiming to create the largest long-read sequencing dataset in the region. This collaboration will provide insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore's multi-ethnic population.
The project includes:
- 60x HiFi depth for Pan-Asian reference genomes
- 20x HiFi depth for multi-omics analysis
- 30x HiFi depth for cancer and rare disease cases
PacBio will establish advanced sequencing infrastructure in Singapore, with Macrogen Asia Pacific Pte as the appointed service provider. The partnership leverages AWS cloud storage for secure data processing and access.
PacBio (NASDAQ: PACB) announced that Novogene is using its Revio long-read sequencing system to expand capabilities at its new lab in Munich, Germany. The Revio system's increased accuracy and throughput are designed to enable Novogene's customers to scale genomic research across rare diseases, cancer, microbes, and agriculture cost-effectively.
Novogene anticipates high demand for Revio from customers in rare disease and cancer research, as well as in microbial and agrigenomics fields. The system's ability to uncover complex repetitive regions, structural variants, and novel isoforms makes it valuable for advanced genomic studies. Novogene plans to integrate more automation into Revio's workflows to increase efficiency and accessibility for a wider range of customers.
PacBio (NASDAQ: PACB) has announced its upcoming second quarter 2024 financial results conference call, scheduled for Wednesday, August 7, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website. For those preferring a dial-in option, toll-free and international numbers are provided. Participants are advised to join the call ten minutes before the start time. This event will provide insights into PacBio's financial performance and potentially discuss key developments in the genomics and life sciences sector.
PacBio (NASDAQ: PACB) and the international Consortium for Long-Read Sequencing (CoLoRS) have launched the first publicly available HiFi long-read variant frequency database. This database, globally representative and free, addresses critical gaps in rare disease research by providing access to genetic variants undetectable through short-read sequencing.
Notably, long-read sequencing detects 15,000 more structural variants and 300,000 more small variants than short-read methods. The CoLoRS database, incorporating data from nearly 1,000 long-read genomes, aids in understanding complex genetic variations and their disease implications. This initiative supports significant advancements in oncology, rare diseases, and genetic disorders research.